Caffeic Acid Enhances the Anti-Leukemic Effect of Imatinib on Chronic Myeloid Leukemia Cells and Triggers Apoptosis in Cells Sensitive and Resistant to Imatinib

Int J Mol Sci. 2021 Feb 6;22(4):1644. doi: 10.3390/ijms22041644.

Abstract

Among the phenolic acids tested on the K562 cell line, a model of chronic myeloid leukemia (CML), caffeic acid (CA) was biologically active on sensitive and imatinib (IM)-resistant cells at micro-molar concentration, either in terms of reduction of cell proliferation or triggering of apoptosis. The CA treatment provoked mitochondrial membrane depolarization, genomic DNA fragmentation and phosphatidylserine exposure, hallmarks of apoptosis. Cell cycle analysis following the treatment with comparable cytotoxic concentrations of IM or CA showed marked differences in the distribution profiles. The reduction of cell proliferation by CA administration was associated with increased expression of two cell cycle repressor genes, CDKN1A and CHES1, while IM at a cytotoxic concentration increased the CHES1 but not the CDKN1A expression. In addition, CA treatment affected the proliferation and triggered the apoptosis in IM-resistant cells. Taken together, these data suggested that CA induced the anti-proliferative effect and triggered apoptosis of CML cells by a different mechanism than IM. Finally, the combined administration of IM and CA at suboptimal concentrations evidenced a synergy of action in determining the anti-proliferative effect and triggering apoptosis. The ability of CA to potentiate the anti-leukemic effect of IM highlighted the nutraceutical potential of CA in CML.

Keywords: apoptosis; caffeic acid; chronic myeloid leukemia; imatinib; resistance.

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Apoptosis / drug effects*
  • Caffeic Acids / pharmacology*
  • Cell Cycle Proteins / biosynthesis
  • Cell Line, Tumor
  • Cell Proliferation / drug effects*
  • Cyclin-Dependent Kinase Inhibitor p21 / biosynthesis
  • DNA Fragmentation / drug effects
  • Drug Resistance, Neoplasm / physiology
  • Drug Synergism
  • Forkhead Transcription Factors / biosynthesis
  • Humans
  • Imatinib Mesylate / pharmacology*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Mitochondrial Membranes / physiology

Substances

  • Antineoplastic Agents
  • CDKN1A protein, human
  • Caffeic Acids
  • Cell Cycle Proteins
  • Cyclin-Dependent Kinase Inhibitor p21
  • FOXN3 protein, human
  • Forkhead Transcription Factors
  • Imatinib Mesylate